Key facts
- Notable investors include Yizhuang Holdings, Chongqing Zhifei Biological Products Company, Comju Capital, Leshan Lechuang Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for XPrecise
- ·The full record, as it builds
Funding rounds
No funding rounds for XPrecise are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About XPrecise
Manufacturer of large-scale medical radiotherapy equipment and precision treatment systems designed to integrate advanced imaging technology with radiation therapy. The company focuses on the research, development, and production of precision radiotherapy solutions, offering integrated imaging-guided treatment systems and related medical technology services, enabling healthcare institutions to deliver accurate, safe, and efficient precision medicine treatments.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2022
- Website
- xprecise-med.com/
- Ownership
- Privately Held (backing)
XPrecise doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in XPrecise shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on XPrecise in its N-PORT filings yet. We sweep new filings monthly.